We are speaking at the 15th Annual WADC San Diego 2024!
We are speaking at the 15th Annual WADC 2024 in San Diego . partnering event in San Diego , 4 – 7 Nov. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
NMS Group S.p.A. Announces Change in Shareholding Structure, Board of Directors and Statutory Auditors to Accelerate Growth and Innovation
NERVIANO, IT, September 11, 2024 – NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote […]
NMS-UPO paper featured on the cover of Chemistry A European Journal
Turning the Impossible into Reality: A chemical astronaut harnesses blue light irradiation to activate Passerini products containing a Hantzsch ester, derived from what are considered “impossible aldehydes.” Be sure to check out the stunning artwork created by Francesca Brunelli, one of the authors of our latest paper in collaboration with Prof. Professor Tron (Università del […]
Nerviano Medical Sciences S.r.l. Announces BRAFTOVI® Royalty Agreement with Blue Owl Capital, potentially exceeding $80 Million
– NMS to receive in excess of $50 Million in upfront cash and milestone payments; total returns capped at a multiple of investment – Financing proceeds will be used to advance NMS’ current pipeline and ADC platform NERVIANO, Italy and BOSTON, Mass., September 5 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) […]
SIMIS S.r.l. Appoints Marco Dieci as CEO to leverage and expand further opportunities at Nerviano Bio-Park
NERVIANO, IT, September 2, 2024 SIMIS S.r.l. (SIMIS), a part of NMS Group S.p.A. (NMS Group) and a company provides services to the community domiciled in Nerviano Bio-Park, today announced the appointment of Marco Dieci as the new Chief Executive Officer, effective immediately. With an exceptional track record in biotechnology, business development and entrepreneurship, Marco […]
Our scientists to speak at the SCI-2024 – XXVIII National Congress
We are honored to have two senior scientists speaking at the SCI-2024 – XXVIII National Congress in Milan. Elena Ardini: Wednesday, August 28th 8:30am – 9:00am Discovery of entrectinib: an amazing journey from target biology to innovative therapy (KN-028) ParallelTopic04: Health Location: Blue1 (level +1) Barbara Valsasina and Gianfranco Pasut, (Dept. Pharmaceutical and Pharmacological Sciences, University of Padova) […]
Nerviano Medical Sciences announces publication of a research paper in “Chemistry – A European Journal”
Thrilled to announce that our latest paper, in collaboration with Prof. Gian Cesare Tron from Università del Piemonte Orientale (UPO), has just been published in the prestigious “Chemistry – A European Journal”! You can check it out here: link. This publication highlights the strong and productive partnership between our two institutions. By building on the […]
We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA)!
We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA) partnering event in WuXi (CHINA) , 10 – 12 Sep. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR) The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2. NMS […]
Nerviano Medical Sciences announces strategic portfolio shaping.
NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, […]
